COVID-19 Information Center
- Coronavirus disease
COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) with safety of associates and patients globally as our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.
Novartis response to COVID-19
In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus disease pandemic.
Study suggests there may be two stages of fatal lung disease in COVID-19
NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.
Information update about the Novartis CAN-COVID trial
The CAN-COVID clinical trial has been one of the ways Novartis is drawing on its global resources and scientific expertise in response to the COVID-19 pandemic.
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19.
COVID-19 update at Q3 2020 Financial Results (Video)
Novartis CEO Vas Narasimhan comments on our efforts to combat COVID-19 at Q3 2020 Financial Results.
1_azwfmd33
Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique
Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.
Choice with Responsibility: Reimagining how we work
Novartis now offers associates the choice to decide how, when and where they work within their country of employment to create the greatest impact for their role while taking personal responsibility to inform managers and align with teammates for effective collaboration, based on the nature of their work.
Our industry is at an inflection point. Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
Sandoz responds to increased demand for antibiotics and other essential medicines for patients during COVID-19
Containing COVID-19 to serve patient needs
The coronavirus crisis has not only challenged the medical community to seek new treatments and vaccines. Keeping up with the production of existing drugs is equally challenging. Novartis has taken a series of measures to maintain production levels and serve millions of patients.
Ensuring medicine supply to patients during COVID-19
Read how two sites within the Novartis Technical Operations (NTO) network ensured business continuity at scale and speed in the midst of the COVID-19 pandemic.
Going the extra mile to keep clinical trials on track during the COVID-19 pandemic
A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.
Novartis COVID-19 Stories
Read how Novartis is approaching the pandemic through the eyes of its associates.
Novartis COVID-19 Response Fund
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
EMG Gold Podcast
Pierre Bourdage, Global Head of Biopharmaceuticals at Sandoz, provides insight into the state and future of the biosimilars market and discusses how to adapt to ‘the new normal’.
How COVID-19 is reshaping the global healthcare ecosystem
On Bloomberg Live, Novartis CEO Vas Narasimhan shares insights on the importance of collaboration during COVID-19.
Leader perspectives during COVID-19
A mini-video-series in which Novartis leaders connect on video calls to discuss some of the biggest questions for healthcare as we navigate the global pandemic.
